Bayer completes sale of H.C. Starck to Advent International and The Carlyle Group
05-Feb-2007
The transaction value of approximately EUR 1.2 billion comprises a cash component of more than EUR 700 million and the assumption of financial liabilities and personnel-related commitments totaling some EUR 450 million. As planned, the proceeds will help to finance Bayer's acquisition of Schering. The divestment reduces Bayer's net debt by about EUR 1 billion.
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.